niacinamide has been researched along with Prostatic Neoplasms in 81 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several case reports suggest sorafenib exposure and sorafenib-induced hyperbilirubinemia may be related to a (TA)(5/6/7) repeat polymorphism in UGT1A1*28 (UGT, uridine glucuronosyl transferase)." | 7.78 | Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. ( Dahut, W; English, BC; Federspiel, J; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kim, A; Kirkland, CT; Kohn, E; Kummar, S; Peer, CJ; Richardson, ED; Sissung, TM; Troutman, SM; Venzon, D; Widemann, B; Woo, S; Yarchoan, R, 2012) |
| "To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice." | 7.76 | Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. ( Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F, 2010) |
| "Acetaldehyde formation was determined by GC-FID analysis in the head space of incubation mixtures." | 5.31 | Rat ventral prostate xanthine oxidase bioactivation of ethanol to acetaldehyde and 1-hydroxyethyl free radicals: analysis of its potential role in heavy alcohol drinking tumor-promoting effects. ( Castro, GD; Castro, JA; Costantini, MH; Delgado de Layño, AM, 2001) |
| "We previously showed that 1-methylnicotinamide (1-MNA) and its analog 1,4-dimethylpyridine (1,4-DMP) could inhibit the formation of lung metastases and enhance the efficacy of cyclophosphamide-based chemotherapy in the model of spontaneously metastasizing 4T1 mouse mammary gland tumors." | 3.85 | The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice. ( Chlopicki, S; Denslow, A; Gebicki, J; Maciejewska, M; Marcinek, A; Nowak, M; Switalska, M; Wietrzyk, J, 2017) |
| "Several case reports suggest sorafenib exposure and sorafenib-induced hyperbilirubinemia may be related to a (TA)(5/6/7) repeat polymorphism in UGT1A1*28 (UGT, uridine glucuronosyl transferase)." | 3.78 | Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. ( Dahut, W; English, BC; Federspiel, J; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kim, A; Kirkland, CT; Kohn, E; Kummar, S; Peer, CJ; Richardson, ED; Sissung, TM; Troutman, SM; Venzon, D; Widemann, B; Woo, S; Yarchoan, R, 2012) |
| "To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice." | 3.76 | Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. ( Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F, 2010) |
| "The objective of this trial was to evaluate the clinical effects of sorafenib, a multi-targeted kinase inhibitor, in combination with androgen receptor blockade in patients with castration-resistant prostate cancer." | 2.77 | A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. ( Beardsley, EK; Chi, KN; Ellard, SL; Hotte, SJ; Kollmannsberger, C; Mukherjee, SD; North, S; Winquist, E, 2012) |
| "We performed a dose-escalation study to investigate the safety of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer (mCRPC)." | 2.77 | Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. ( Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S, 2012) |
| "Sorafenib was given at a dose of 400 mg orally twice daily in 28-day cycles." | 2.74 | Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. ( Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Draper, D; Figg, WD; Gulley, JL; Jain, L; Jones, E; Steinberg, SM; Venitz, J; Wright, JJ, 2009) |
| "Sorafenib is a multi-kinase inhibitor with antiangiogenic and antiproliferative activity." | 2.73 | A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. ( Burkholder, I; Dittrich, C; Edler, L; Frost, A; Gillessen, S; Hanauske, AR; Hochhaus, A; Morant, R; Mross, K; Scheulen, M; Steinbild, S; Strumberg, D, 2007) |
| "Sorafenib 400 mg was administered orally twice daily continuously." | 2.73 | A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. ( Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W, 2008) |
| "Sorafenib was given continuously at a dose of 400 mg orally twice daily in 28-day cycles." | 2.73 | A phase II clinical trial of sorafenib in androgen-independent prostate cancer. ( Aragon-Ching, JB; Arlen, PM; Cao, L; Chen, CC; Dahut, WL; Figg, WD; Gulley, JL; Jain, L; Jones, E; Posadas, E; Scripture, C; Steinberg, SM; Venitz, J; Wright, JJ; Yu, Y, 2008) |
| "Despite multiple advances in prostate cancer therapy, treatment options for castration resistant disease are very limited." | 2.47 | Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. ( Espinosa, E; González, R; Merino, M; Pinto, A, 2011) |
| "A 73-year-old man with prostate cancer underwent [18F]PSMA-1007 PET/CT for biochemical recurrence." | 1.72 | Incidental [18F]PSMA-1007 Appendiceal Uptake Mimicking Nodal Disease. ( Lyburn, ID; Nawwar, AA; Searle, J, 2022) |
| "PSMA is overexpressed in prostate cancer but also expressed in a variety of benign and malignant conditions." | 1.72 | Tubercular Spondylitis: A Rare Complication of BCGosis Masquerading as Metastasis on 18F-PSMA-1007 PET/CT. ( Bohil, A; Fernando, R; Rathi, N; Seshadri, N; Vinjamuri, S, 2022) |
| "The subsequent bone biopsy revealed multiple myeloma." | 1.72 | Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential? ( Engelhardt, M; Jilg, CA; Meyer, PT; Michalski, K; Ruf, J, 2022) |
| "We present images of metastatic prostate cancer in two patients, where 64Cu-PSMA PET/CT was performed one day after 18F-PSMA-1007 PET/CT." | 1.72 | A Comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 Patients With Metastatic Prostate Cancer. ( Cardoza-Ochoa, DR; Rivera-Bravo, B, 2022) |
| "Bone biopsy confirmed metastases of prostate cancer." | 1.62 | False-Positive 18F-Prostate-Specific Membrane Antigen-1007 PET/CT Caused by Hepatic Multifocal Inflammatory Foci. ( Canelo, A; Ladrón-de-Guevara, D; Piottante, A; Regonesi, C, 2021) |
| "A 70-year-old man with newly diagnosed prostate cancer underwent 18F-PSMA-1007 PET/CT for staging." | 1.62 | COVID-19-Related Lung Parenchymal Uptake on 18F-PSMA-1007 PET/CT. ( Green, JS; Lyburn, ID; Nawwar, AA; Searle, J, 2021) |
| "DU145 prostate cancer cells were exposed to chemotherapy (free and liposomal Sorafenib) and ablative HIFU, alone or in combination." | 1.43 | Ablative Focused Ultrasound Synergistically Enhances Thermally Triggered Chemotherapy for Prostate Cancer in Vitro. ( Arora, JS; Ashe, S; Halliburton, G; He, J; John, VT; Khismatullin, DB; Murad, HY; Yu, H, 2016) |
| "Prostate cancer is the second leading cause of male cancer death in developed countries." | 1.40 | Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib. ( Bernardini, M; Brossa, A; Bussolati, B; Fiorio Pla, A; Genova, T; Gkika, D; Grolez, G; Leroy, X; Prevarskaya, N; Villers, A, 2014) |
| "In sorafenib-treated tumors, PS (0." | 1.39 | In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media. ( Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Hinkel, R; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; Sourbron, S; von Einem, JC; Wintersperger, BJ, 2013) |
| "In sorafenib-treated tumors, significantly more apoptotic cells (TUNEL; 7132 ± 3141 vs." | 1.38 | Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. ( Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Eschbach, R; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; von Einem, JC; Wintersperger, BJ, 2012) |
| "In sorafenib-treated tumors, significantly more apoptotic cells (terminal deoxynucleotidyl transferase-mediated nick end labeling, 6923 ± 3761 vs 3167 ± 1500; p < 0." | 1.38 | Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study. ( Bruns, CJ; Cyran, CC; Dietrich, O; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Pietsch, H; Reiser, MF; Schwarz, B; Sourbron, S; von Einem, J; Wintersperger, BJ, 2012) |
| "Sorafenib stimulated apoptosis in prostate cancer cell lines through downregulation of myeloid cell leukemia-1 (MCL-1) expression and Akt phosphorylation." | 1.38 | Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. ( Culig, Z; Erb, HH; Hobisch, A; Oh, SJ; Santer, FR, 2012) |
| "Prostate cancer is the most common malignancy in men, and patients with metastatic disease have poor outcome even with the most advanced therapeutic approaches." | 1.36 | The effects of telomerase inhibition on prostate tumor-initiating cells. ( Marian, CO; Shay, JW; Wright, WE, 2010) |
| "Human androgen-independent PC-3 prostate cancer cells were treated with sorafenib." | 1.36 | The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. ( Chen, N; Chen, XQ; Huang, R; Huang, Y; Zeng, H, 2010) |
| "Acetaldehyde formation was determined by GC-FID analysis in the head space of incubation mixtures." | 1.31 | Rat ventral prostate xanthine oxidase bioactivation of ethanol to acetaldehyde and 1-hydroxyethyl free radicals: analysis of its potential role in heavy alcohol drinking tumor-promoting effects. ( Castro, GD; Castro, JA; Costantini, MH; Delgado de Layño, AM, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.23) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (13.58) | 29.6817 |
| 2010's | 39 (48.15) | 24.3611 |
| 2020's | 30 (37.04) | 2.80 |
| Authors | Studies |
|---|---|
| Nawwar, AA | 2 |
| Searle, J | 2 |
| Lyburn, ID | 2 |
| Alberts, I | 3 |
| Mingels, C | 2 |
| Zacho, HD | 1 |
| Lanz, S | 1 |
| Schöder, H | 1 |
| Rominger, A | 3 |
| Zwahlen, M | 1 |
| Afshar-Oromieh, A | 3 |
| Bohil, A | 1 |
| Seshadri, N | 1 |
| Rathi, N | 1 |
| Fernando, R | 1 |
| Vinjamuri, S | 1 |
| Bohn, KP | 1 |
| Lengana, T | 1 |
| Lawal, I | 1 |
| Janse Van Rensburg, C | 1 |
| Mokoala, K | 1 |
| Moshokoa, E | 1 |
| Mazibuko, S | 1 |
| Van de Wiele, C | 1 |
| Maes, A | 1 |
| Vorster, M | 1 |
| Sathekge, MM | 1 |
| Deleu, AL | 1 |
| Ahmadi Bidakhvidi, N | 1 |
| Van Wynsberge, L | 1 |
| Van Laere, K | 1 |
| De Meerleer, G | 1 |
| Goffin, K | 1 |
| Michalski, K | 1 |
| Jilg, CA | 1 |
| Engelhardt, M | 1 |
| Meyer, PT | 1 |
| Ruf, J | 1 |
| Sadeq, A | 1 |
| Usmani, S | 2 |
| Esmail, AA | 1 |
| Fathallah, W | 1 |
| Alfeeli, MA | 1 |
| Marafi, F | 2 |
| Kisiel, N | 1 |
| Thomas, P | 1 |
| Bütikofer, L | 1 |
| Sharma, P | 1 |
| Watts, A | 1 |
| Singh, H | 1 |
| Yao, F | 1 |
| Bian, S | 1 |
| Zhu, D | 1 |
| Yuan, Y | 1 |
| Pan, K | 1 |
| Pan, Z | 1 |
| Feng, X | 1 |
| Tang, K | 4 |
| Yang, Y | 1 |
| Hvittfeldt, E | 1 |
| Bjöersdorff, M | 1 |
| Brolin, G | 1 |
| Minarik, D | 1 |
| Svegborn, SL | 1 |
| Oddstig, J | 1 |
| Trägårdh, E | 1 |
| Witkowska-Patena, E | 3 |
| Giżewska, A | 3 |
| Dziuk, M | 3 |
| Miśko, J | 3 |
| Budzyńska, A | 2 |
| Walęcka-Mazur, A | 2 |
| Wang, Z | 1 |
| Lin, J | 3 |
| Zheng, X | 1 |
| Hartrampf, PE | 1 |
| Seitz, AK | 1 |
| Krebs, M | 1 |
| Buck, AK | 1 |
| Lapa, C | 1 |
| Cardinale, J | 3 |
| Roscher, M | 1 |
| Schäfer, M | 1 |
| Geerlings, M | 1 |
| Benešová, M | 1 |
| Bauder-Wüst, U | 1 |
| Remde, Y | 1 |
| Eder, M | 1 |
| Nováková, Z | 1 |
| Motlová, L | 1 |
| Barinka, C | 1 |
| Giesel, FL | 5 |
| Kopka, K | 4 |
| Privé, BM | 1 |
| Israël, B | 1 |
| Schilham, MGM | 1 |
| Muselaers, CHJ | 1 |
| Zámecnik, P | 1 |
| Mulders, PFA | 1 |
| Witjes, JA | 1 |
| Sedelaar, M | 1 |
| Mehra, N | 1 |
| Verzijlbergen, F | 1 |
| Janssen, MJR | 1 |
| Gotthardt, M | 1 |
| Barentsz, JO | 1 |
| van Oort, IM | 1 |
| Nagarajah, J | 1 |
| Soeda, F | 2 |
| Watabe, T | 2 |
| Kato, H | 2 |
| Uemura, M | 2 |
| Nonomura, N | 2 |
| Ladrón-de-Guevara, D | 1 |
| Canelo, A | 1 |
| Piottante, A | 1 |
| Regonesi, C | 1 |
| Naka, S | 1 |
| Ujike, T | 1 |
| Hatano, K | 1 |
| Sasaki, H | 1 |
| Kamiya, T | 1 |
| Shimosegawa, E | 1 |
| Tateishi, U | 1 |
| Liu, BL | 1 |
| Hong, JJ | 1 |
| Zheng, XW | 1 |
| Campaña, J | 1 |
| Bernal, P | 1 |
| Cardoza-Ochoa, DR | 1 |
| Rivera-Bravo, B | 1 |
| Green, JS | 1 |
| Grünig, H | 1 |
| Maurer, A | 1 |
| Thali, Y | 1 |
| Kovacs, Z | 1 |
| Strobel, K | 1 |
| Burger, IA | 1 |
| Müller, J | 1 |
| Malaspina, S | 1 |
| Anttinen, M | 1 |
| Taimen, P | 1 |
| Löyttyniemi, E | 1 |
| Kemppainen, J | 1 |
| Seppänen, M | 1 |
| Boström, P | 1 |
| Ettala, O | 1 |
| E, AJYP | 1 |
| R, S | 1 |
| P, S | 1 |
| K, L | 1 |
| S, A | 1 |
| Ji, X | 1 |
| Wang, L | 1 |
| Alfeeli, M | 1 |
| Esmail, A | 1 |
| Fathallah, WMA | 1 |
| Paddubny, K | 2 |
| Freitag, MT | 1 |
| Kratochwil, C | 3 |
| Koerber, S | 1 |
| Radtke, JP | 2 |
| Sakovich, R | 1 |
| Will, L | 1 |
| Kremer, C | 1 |
| Rathke, H | 1 |
| Haufe, S | 1 |
| Haberkorn, U | 2 |
| Rahbar, K | 2 |
| Weckesser, M | 2 |
| Ahmadzadehfar, H | 1 |
| Schäfers, M | 1 |
| Stegger, L | 1 |
| Bögemann, M | 2 |
| Panagiotidis, E | 1 |
| Paschali, A | 1 |
| Giannoula, E | 1 |
| Chatzipavlidou, V | 1 |
| Seifert, R | 1 |
| Schafigh, D | 1 |
| Chen, X | 1 |
| Che, X | 1 |
| Wang, J | 1 |
| Chen, F | 1 |
| Wang, X | 1 |
| Zhang, Z | 1 |
| Fan, B | 1 |
| Yang, D | 1 |
| Song, X | 1 |
| Yang, SH | 2 |
| Song, CH | 2 |
| Van, HT | 1 |
| Park, E | 2 |
| Khadka, DB | 2 |
| Gong, EY | 2 |
| Lee, K | 2 |
| Cho, WJ | 2 |
| Zhang, K | 1 |
| Waxman, DJ | 1 |
| Cyran, CC | 3 |
| Schwarz, B | 3 |
| Paprottka, PM | 3 |
| Sourbron, S | 2 |
| von Einem, JC | 2 |
| Dietrich, O | 3 |
| Hinkel, R | 3 |
| Clevert, DA | 2 |
| Bruns, CJ | 3 |
| Reiser, MF | 3 |
| Nikolaou, K | 3 |
| Wintersperger, BJ | 3 |
| Young, A | 1 |
| Berry, R | 1 |
| Holloway, AF | 1 |
| Blackburn, NB | 1 |
| Dickinson, JL | 1 |
| Skala, M | 1 |
| Phillips, JL | 1 |
| Brettingham-Moore, KH | 1 |
| Yu, P | 2 |
| Ye, L | 2 |
| Wang, H | 2 |
| Du, G | 2 |
| Zhang, J | 4 |
| Tian, J | 2 |
| Fiorio Pla, A | 1 |
| Brossa, A | 1 |
| Bernardini, M | 1 |
| Genova, T | 1 |
| Grolez, G | 1 |
| Villers, A | 1 |
| Leroy, X | 1 |
| Prevarskaya, N | 1 |
| Gkika, D | 1 |
| Bussolati, B | 1 |
| Zuo, Y | 1 |
| Yamamoto, Y | 1 |
| De Velasco, MA | 1 |
| Kura, Y | 1 |
| Nozawa, M | 1 |
| Hatanaka, Y | 1 |
| Oki, T | 1 |
| Ozeki, T | 1 |
| Shimizu, N | 1 |
| Minami, T | 1 |
| Yoshimura, K | 1 |
| Yoshikawa, K | 1 |
| Nishio, K | 1 |
| Uemura, H | 1 |
| Kharaziha, P | 3 |
| Chioureas, D | 1 |
| Baltatzis, G | 1 |
| Fonseca, P | 1 |
| Rodriguez, P | 2 |
| Gogvadze, V | 1 |
| Lennartsson, L | 2 |
| Björklund, AC | 2 |
| Zhivotovsky, B | 1 |
| Grandér, D | 3 |
| Egevad, L | 2 |
| Nilsson, S | 3 |
| Panaretakis, T | 3 |
| Mirantes, C | 1 |
| Dosil, MA | 1 |
| Eritja, N | 1 |
| Felip, I | 1 |
| Gatius, S | 1 |
| Santacana, M | 1 |
| Matias-Guiu, X | 1 |
| Dolcet, X | 1 |
| Arora, JS | 1 |
| Murad, HY | 1 |
| Ashe, S | 1 |
| Halliburton, G | 1 |
| Yu, H | 1 |
| He, J | 1 |
| John, VT | 1 |
| Khismatullin, DB | 1 |
| Kesch, C | 1 |
| Yun, M | 1 |
| Hadaschik, BA | 1 |
| Denslow, A | 1 |
| Switalska, M | 1 |
| Nowak, M | 1 |
| Maciejewska, M | 1 |
| Chlopicki, S | 1 |
| Marcinek, A | 1 |
| Gebicki, J | 1 |
| Wietrzyk, J | 1 |
| Colloca, G | 1 |
| Checcaglini, F | 1 |
| Venturino, A | 1 |
| Jung-Hynes, B | 1 |
| Nihal, M | 1 |
| Zhong, W | 1 |
| Ahmad, N | 1 |
| Aragon-Ching, JB | 4 |
| Jain, L | 3 |
| Gulley, JL | 2 |
| Arlen, PM | 2 |
| Wright, JJ | 2 |
| Steinberg, SM | 2 |
| Draper, D | 1 |
| Venitz, J | 2 |
| Jones, E | 2 |
| Chen, CC | 2 |
| Figg, WD | 3 |
| Dahut, WL | 4 |
| Marian, CO | 1 |
| Wright, WE | 1 |
| Shay, JW | 1 |
| Huang, R | 1 |
| Chen, XQ | 1 |
| Huang, Y | 1 |
| Chen, N | 1 |
| Zeng, H | 1 |
| Ullén, A | 2 |
| Farnebo, M | 1 |
| Thyrell, L | 1 |
| Mahmoudi, S | 1 |
| Bono, AV | 1 |
| Pannellini, T | 1 |
| Liberatore, M | 1 |
| Montironi, R | 1 |
| Cunico, SC | 1 |
| Cheng, L | 1 |
| Sasso, F | 1 |
| Musiani, P | 1 |
| Iezzi, M | 1 |
| Wallach, I | 1 |
| Jaitly, N | 1 |
| Lilien, R | 1 |
| Merino, M | 1 |
| Pinto, A | 1 |
| González, R | 1 |
| Espinosa, E | 1 |
| Beardsley, EK | 1 |
| Hotte, SJ | 2 |
| North, S | 1 |
| Ellard, SL | 2 |
| Winquist, E | 1 |
| Kollmannsberger, C | 1 |
| Mukherjee, SD | 1 |
| Chi, KN | 2 |
| Ingrisch, M | 2 |
| Eschbach, R | 1 |
| Lian, J | 1 |
| Ni, Z | 1 |
| Dai, X | 1 |
| Su, C | 1 |
| Smith, AR | 1 |
| Xu, L | 1 |
| He, F | 1 |
| von Einem, J | 1 |
| Pietsch, H | 1 |
| Li, Q | 1 |
| Rundqvist, H | 1 |
| Augsten, M | 1 |
| Wiklund, P | 1 |
| Kroemer, G | 1 |
| Peer, CJ | 1 |
| Sissung, TM | 1 |
| Kim, A | 1 |
| Woo, S | 1 |
| Gardner, ER | 1 |
| Kirkland, CT | 1 |
| Troutman, SM | 1 |
| English, BC | 1 |
| Richardson, ED | 1 |
| Federspiel, J | 1 |
| Venzon, D | 1 |
| Dahut, W | 2 |
| Kohn, E | 1 |
| Kummar, S | 1 |
| Yarchoan, R | 1 |
| Giaccone, G | 1 |
| Widemann, B | 1 |
| Oh, SJ | 1 |
| Erb, HH | 1 |
| Hobisch, A | 1 |
| Santer, FR | 1 |
| Culig, Z | 1 |
| Mardjuadi, F | 1 |
| Medioni, J | 1 |
| Kerger, J | 1 |
| D'Hondt, L | 1 |
| Canon, JL | 1 |
| Duck, L | 1 |
| Musuamba, F | 1 |
| Oudard, S | 1 |
| Clausse, M | 1 |
| Moxhon, A | 1 |
| Machiels, JP | 1 |
| Cho, SH | 1 |
| Nabhan, C | 1 |
| Villines, D | 1 |
| Valdez, TV | 1 |
| Tolzien, K | 1 |
| Lestingi, TM | 1 |
| Bitran, JD | 1 |
| Christner, SM | 1 |
| Egorin, MJ | 1 |
| Beumer, JH | 1 |
| Török, S | 1 |
| Cserepes T, M | 1 |
| Rényi-Vámos, F | 1 |
| Döme, B | 1 |
| Kong, HH | 1 |
| Cowen, EW | 1 |
| Azad, NS | 1 |
| Gutierrez, M | 1 |
| Turner, ML | 1 |
| Tan, W | 1 |
| Steinbild, S | 1 |
| Mross, K | 1 |
| Frost, A | 1 |
| Morant, R | 1 |
| Gillessen, S | 1 |
| Dittrich, C | 1 |
| Strumberg, D | 1 |
| Hochhaus, A | 1 |
| Hanauske, AR | 1 |
| Edler, L | 1 |
| Burkholder, I | 1 |
| Scheulen, M | 1 |
| Czaykowski, P | 1 |
| Moore, M | 1 |
| Ruether, JD | 1 |
| Schell, AJ | 1 |
| Taylor, S | 1 |
| Hansen, C | 1 |
| Gauthier, I | 1 |
| Walsh, W | 1 |
| Seymour, L | 1 |
| Scripture, C | 1 |
| Posadas, E | 1 |
| Yu, Y | 1 |
| Cao, L | 1 |
| Faintuch, BL | 1 |
| Teodoro, R | 1 |
| Duatti, A | 1 |
| Muramoto, E | 1 |
| Faintuch, S | 1 |
| Smith, CJ | 1 |
| Castro, GD | 1 |
| Delgado de Layño, AM | 1 |
| Costantini, MH | 1 |
| Castro, JA | 1 |
| Wolf, H | 1 |
| Brown, RR | 1 |
| Price, JM | 1 |
| Madsen, PO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 for the Detection of Recurrent Prostate Cancer in PSMA-ligand PET/CT[NCT05079828] | 100 participants (Anticipated) | Interventional | 2022-07-07 | Recruiting | |||
| 18F-PSMA-1007 PET to Detect Primary Prostate Cancer: a Comparative Study With mpMRI and Correlation to Histopathology[NCT04487847] | Phase 1/Phase 2 | 75 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer[NCT00090545] | Phase 2 | 46 participants (Actual) | Interventional | 2004-09-01 | Completed | ||
| A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer[NCT00093457] | Phase 2 | 28 participants (Actual) | Interventional | 2004-08-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Geometric mean exposure for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | mg/L.h (Geometric Mean) |
|---|---|
| First Stage - Disease Progression | 9.76 |
| Second Stage - Increased Accrual | 18.63 |
Plasma concentration-time profile for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, AND 24 hours post dose
| Intervention | mg/L (Mean) |
|---|---|
| First Stage - Disease Progression | 1.28 |
| Second Stage - Increased Accrual | 2.57 |
Time from treatment start date until date of death or date last known alive. (NCT00090545)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 18.3 months.
| Intervention | Months (Median) |
|---|---|
| First Stage - Disease Progression | 18 |
| Second Stage - Increased Accrual | 18.3 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT00090545)
Timeframe: Date treatment consent signed to date off study, approximately 49 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| First Stage - Disease Progression | 22 |
| Second Stage - Increased Accrual | 23 |
Determine whether BAY 43-9006 when used to treat metastatic prostate cancer is associated with having 50% of Patients Progression Free at 4 Months by clinical, radiographic, and prostatic specific antigen (PSA)criteria. (NCT00090545)
Timeframe: 4 months
| Intervention | months (Median) |
|---|---|
| First Stage - Disease Progression | 1.83 |
| Second Stage - Increased Accrual | 3.7 |
Time to maximum concentration for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | hours (Median) |
|---|---|
| First Stage - Disease Progression | 0.68 |
| Second Stage - Increased Accrual | 8 |
Overall response was evaluated by the RECIST. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00090545)
Timeframe: Every 2 cycles (1 cycle = 28 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| First Stage - Disease Progression | 0 | 0 | 8 | 0 |
| Second Stage - Increased Accrual | 0 | 1 | 13 | 10 |
5 reviews available for niacinamide and Prostatic Neoplasms
| Article | Year |
|---|---|
The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.
Topics: Aged; Aged, 80 and over; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Middle | 2022 |
VEGF inhibitors and prostate cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; | 2011 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Tri | 2012 |
[Promising new treatment options for metastatic androgen-independent prostate cancer].
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
9 trials available for niacinamide and Prostatic Neoplasms
| Article | Year |
|---|---|
A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale.
Topics: Edetic Acid; Gallium Radioisotopes; Humans; Ligands; Male; Neoplasm Recurrence, Local; Niacinamide; | 2022 |
Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Niacinamide; Oligopeptides; Positron Em | 2019 |
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Disease-Free Surv | 2009 |
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; D | 2012 |
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenes | 2012 |
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Fatigue; Humans; Male; Middle Age | 2007 |
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antin | 2008 |
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Extracellular Signal-Regulate | 2008 |
67 other studies available for niacinamide and Prostatic Neoplasms
| Article | Year |
|---|---|
Incidental [18F]PSMA-1007 Appendiceal Uptake Mimicking Nodal Disease.
Topics: Aged; Appendix; Gallium Radioisotopes; Humans; Male; Niacinamide; Oligopeptides; Positron Emission T | 2022 |
Comparing the clinical performance and cost efficacy of [
Topics: Decision Support Techniques; Edetic Acid; Fluorine Radioisotopes; Gallium Isotopes; Gallium Radioiso | 2022 |
Tubercular Spondylitis: A Rare Complication of BCGosis Masquerading as Metastasis on 18F-PSMA-1007 PET/CT.
Topics: Gallium Radioisotopes; Humans; Male; Niacinamide; Oligopeptides; Positron Emission Tomography Comput | 2022 |
Diagnostic accuracy of [
Topics: Gallium Radioisotopes; Humans; Male; Niacinamide; Oligopeptides; Positron Emission Tomography Comput | 2022 |
[
Topics: Gallium Radioisotopes; Humans; Male; Niacinamide; Oligopeptides; Positron Emission Tomography Comput | 2022 |
Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential?
Topics: Aged; Bone Marrow; Gallium Radioisotopes; Humans; Male; Multiple Myeloma; Niacinamide; Oligopeptides | 2022 |
Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
Topics: Adult; Brain; Carcinoma, Renal Cell; Gallium Radioisotopes; Humans; Kidney Neoplasms; Male; Niacinam | 2022 |
Potential Pitfall in the Interpretation of Ganglioneuronal Uptake of 18 F-PSMA-1007 PET/CT Scans Performed With a High Spatial Resolution Digital PET Scanner.
Topics: Aged; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Neoplasm Recurrence, Local | 2022 |
Comparison of Internal Dosimetry of 18 F-PSMA-1007 and 68 Ga-PSMA-11-HBED-CC.
Topics: Edetic Acid; Fluorine Radioisotopes; Gallium Radioisotopes; Humans; Ligands; Male; Niacinamide; Olig | 2022 |
Machine learning-based radiomics for multiple primary prostate cancer biological characteristics prediction with
Topics: Fluorine Radioisotopes; Humans; Machine Learning; Male; Neoplasms, Multiple Primary; Niacinamide; Ol | 2022 |
Biokinetics and dosimetry of
Topics: Humans; Ligands; Male; Niacinamide; Oligopeptides; Positron Emission Tomography Computed Tomography; | 2022 |
Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml.
Topics: Aged; Aged, 80 and over; Fluorine Radioisotopes; Follow-Up Studies; Humans; Male; Middle Aged; Neopl | 2020 |
Hürthle Cell Thyroid Adenoma Showing Avid Uptake on 18F-PSMA-1007 PET/CT.
Topics: Adenoma, Oxyphilic; Aged; Biological Transport; Fluorine Radioisotopes; Humans; Male; Neoplasm Stagi | 2020 |
False-negative
Topics: Aged; Humans; Liver; Male; Niacinamide; Oligopeptides; Positron Emission Tomography Computed Tomogra | 2020 |
Development of PSMA-1007-Related Series of
Topics: Antigens, Surface; Fluorine Radioisotopes; Glutamate Carboxypeptidase II; Humans; Ligands; Male; Nia | 2020 |
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology.
Topics: Aged; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multiparametric Magnetic | 2021 |
Duodenal Adenocarcinoma Mimicking Metastasis of Prostate Cancer on 18F-Prostate-Specific Membrane Antigen-1007 PET/CT.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; Duodenal Neoplasms; Humans; Male; Neoplasm Grading; N | 2021 |
False-Positive 18F-Prostate-Specific Membrane Antigen-1007 PET/CT Caused by Hepatic Multifocal Inflammatory Foci.
Topics: Aged; Biopsy; Bone Neoplasms; False Positive Reactions; Fluorine Radioisotopes; Humans; Inflammation | 2021 |
High detection rate in [
Topics: Aged; Bone Neoplasms; Diagnostic Imaging; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm R | 2021 |
18F-PSMA-1007 Uptake in Pulmonary Lymphangitic Carcinomatosis Metastasis From Prostate Cancer.
Topics: Biological Transport; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Oligopeptides; Positro | 2021 |
Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavorable intermediate and high-risk prostate cancer.
Topics: Humans; Magnetic Resonance Imaging; Male; Niacinamide; Oligopeptides; Positron Emission Tomography C | 2021 |
A Comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 Patients With Metastatic Prostate Cancer.
Topics: Copper Radioisotopes; Gallium Radioisotopes; Humans; Male; Niacinamide; Oligopeptides; Positron Emis | 2022 |
COVID-19-Related Lung Parenchymal Uptake on 18F-PSMA-1007 PET/CT.
Topics: Aged; COVID-19; Edetic Acid; Humans; Lung; Male; Neoplasm Staging; Niacinamide; Oligopeptides; Posit | 2021 |
Focal unspecific bone uptake on [
Topics: Edetic Acid; Humans; Male; Niacinamide; Oligopeptides; Positron Emission Tomography Computed Tomogra | 2021 |
Response to the Letter to the Editor: Prospective comparison of
Topics: Humans; Magnetic Resonance Imaging; Male; Niacinamide; Oligopeptides; Positron Emission Tomography C | 2021 |
Experimental, and theoretical investigations on the structure and vibrational spectral analysis of oxalate complex of nicotinamide and computational scrutiny against prostate cancer.
Topics: Humans; Male; Models, Molecular; Molecular Docking Simulation; Niacinamide; Oxalates; Prostatic Neop | 2022 |
Detection of Diffuse Peritoneal and Omental Metastases From Prostate Cancer With 18F-PSMA-1007 PET/CT.
Topics: Aged, 80 and over; Humans; Male; Neoplasm Metastasis; Niacinamide; Oligopeptides; Peritoneum; Positr | 2022 |
18F-PSMA-1007 Uptake in Paget Disease of the Bone: An "Iron Man" Sign.
Topics: Aged, 80 and over; Edetic Acid; Gallium Radioisotopes; Humans; Male; Niacinamide; Oligopeptides; Ost | 2022 |
Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy.
Topics: Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; N | 2018 |
[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty.
Topics: Arthroplasty; Fluorine Radioisotopes; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local | 2018 |
Advantage of
Topics: Edetic Acid; Fluorine Radioisotopes; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Neoplasm | 2018 |
Rib Fractures Mimicking Bone Metastases in 18F-PSMA-1007 PET/CT for Prostate Cancer.
Topics: Aged; Bone Neoplasms; Diagnosis, Differential; Fluorine Radioisotopes; Humans; Male; Niacinamide; Ol | 2019 |
Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007.
Topics: Fluorine Radioisotopes; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Oligopep | 2019 |
18F-Prostate-Specific Membrane Antigen 1007 and 18F-FCH PET/CT in Local Recurrence of Prostate Cancer.
Topics: Aged; Choline; Fluorine Radioisotopes; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Oligop | 2019 |
Zinc sensitizes prostate cancer cells to sorafenib and regulates the expression of Livin.
Topics: Actins; Adaptor Proteins, Signal Transducing; Apoptosis; Cell Line, Tumor; Cell Survival; Cytoskelet | 2013 |
SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Cell Line, Tumor; Drug Design; Humans; Isoquino | 2013 |
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Dise | 2013 |
In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Contrast Media; Image Enhancement; Immunohi | 2013 |
RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.
Topics: Biomarkers, Tumor; BRCA1 Protein; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; DNA Repair; | 2014 |
NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, | 2015 |
Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Pr | 2014 |
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival | 2014 |
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Disease Mode | 2015 |
Sorafenib-induced defective autophagy promotes cell death by necroptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western | 2015 |
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neo | 2016 |
Ablative Focused Ultrasound Synergistically Enhances Thermally Triggered Chemotherapy for Prostate Cancer in Vitro.
Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cryoelectron Microscopy; Drug Delivery S | 2016 |
18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer.
Topics: Aged; Fluorine Radioisotopes; Humans; Male; Neoplasm Micrometastasis; Neoplasm Recurrence, Local; Ni | 2017 |
The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Models, Animal; D | 2017 |
About sorafenib in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Male; Niacinamide; Orchiectomy; Phenylurea Compoun | 2008 |
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?
Topics: Adult; Aged; Benzamides; Cell Line, Tumor; Forkhead Box Protein O1; Forkhead Transcription Factors; | 2009 |
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Hum | 2010 |
The effects of telomerase inhibition on prostate tumor-initiating cells.
Topics: Cell Line, Tumor; Humans; Indoles; Male; Neoplastic Stem Cells; Niacinamide; Oligonucleotides; Prost | 2010 |
The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.
Topics: Apoptosis; Benzenesulfonates; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Extracellular Si | 2010 |
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Carcinoma; Drug Evaluation, Preclini | 2010 |
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Disease | 2010 |
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways.
Topics: Breast Neoplasms; Computational Biology; Databases, Factual; Diabetes Mellitus, Type 2; Drug-Related | 2010 |
Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Cell Line, Tumor; Contrast Media; Ioh | 2012 |
Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Topics: Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-2 Homo | 2012 |
Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Humans; Image Interpretation, Com | 2012 |
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma; Cell Line, | 2012 |
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bilirubin; Clinical Trials as Topi | 2012 |
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Caspa | 2012 |
Structure-based virtual screening and identification of a novel androgen receptor antagonist.
Topics: Androgen Receptor Antagonists; Animals; Chlorocebus aethiops; COS Cells; Drug Screening Assays, Anti | 2012 |
Keratoacanthomas associated with sorafenib therapy.
Topics: Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Facial Dermatoses; Female; Humans; Keratoacanth | 2007 |
Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies.
Topics: Animals; Bombesin; Cell Line, Tumor; Cysteine; Disease Models, Animal; Drug Design; Drug Evaluation, | 2008 |
Rat ventral prostate xanthine oxidase bioactivation of ethanol to acetaldehyde and 1-hydroxyethyl free radicals: analysis of its potential role in heavy alcohol drinking tumor-promoting effects.
Topics: Acetaldehyde; Alcohol Drinking; Allopurinol; Animals; Antimetabolites; Caffeine; Carcinogens; Chroma | 2001 |
Effect of hormones on the biosynthesis of nicotinic acid from tryptophan in man.
Topics: Carboxy-Lyases; Chlorotrianisene; Chromatography, Ion Exchange; Diethylstilbestrol; Humans; Hydrocor | 1970 |